REG - GlaxoSmithKline PLC - Director/PDMR Shareholding
14/01/2022 15:25
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220114:nRSN5328Ya&default-theme=true
RNS Number : 5328Y GlaxoSmithKline PLC 14 January 2022
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms E Walmsley
b) Position/status Chief Executive Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 13 January 2022, on shares held through the Company's Share
Reward Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3528 28
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-01-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr R Connor
b) Position/status President, Vaccines & Global Health
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 13 January 2022, on shares held through the Company's Share
Reward Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3528 77
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-01-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms D Conrad
b) Position/status SVP, Human Resources
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 13 January 2022, on shares held through the Company's Share
Reward Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3528 6
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-01-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr J Ford
b) Position/status SVP & General Counsel
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 13 January 2022, on shares held through the Company's Share
Reward Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3528 4
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-01-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms S Jackson
b) Position/status SVP, Global Communications and CEO Office
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 13 January 2022, on shares held through the Company's Share
Reward Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3528 72
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-01-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr D Jackson
b) Position/status PCA of Ms S Jackson (SVP, Global Communications and CEO Office)
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 13 January 2022, on shares held through the Company's Share
Reward Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3528 28
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-01-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr L Miels
b) Position/status Chief Commercial Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 13 January 2022, on shares held through the Company's Share
Reward Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3528 4
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-01-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr D Redfern
b) Position/status Chief Strategy Officer
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 13 January 2022, on shares held through the Company's Share
Reward Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3528 87
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-01-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr R Simard
b) Position/status President, Pharmaceuticals Supply Chain
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 13 January 2022, on shares held through the Company's Share
Reward Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3528 28
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-01-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Mr P Thomson
b) Position/status President, Global Affairs
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 13 January 2022, on shares held through the Company's Share
Reward Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3528 52
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-01-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms D Waterhouse
b) Position/status Chief Executive Officer of ViiV Healthcare
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 13 January 2022, on shares held through the Company's Share
Reward Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3528 70
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-01-13
f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
a) Name Ms V Whyte
b) Position/status Company Secretary
c) Initial notification/ Initial notification
amendment
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid
to shareholders on 13 January 2022, on shares held through the Company's Share
Reward Plan.
c) Price(s) and volume(s) Price(s) Volume(s)
£16.3528 65
d) Aggregated information N/A (single transaction)
Aggregated volume Price
e) Date of the transaction 2022-01-13
f) Place of the transaction London Stock Exchange (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHEZLFFLFLLBBBRecent news on GSK
See all newsREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Transaction in Own Shares
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - GSK submits Arexvy for adults 18+ with EMA
AnnouncementREG - GSK PLC - Transaction in Own Shares
Announcement